Category Archives: Spinal Cord Injury Treatment

Stamford, CT (PRWEB) April 01, 2013 Medical marketing firm MCPR introduces spinal cord injury expert Dr. Argyrios Stampas for media interviews. Dr. Stampas is the Director of Burke Rehabilitation Hospitals Spinal Cord Injury Program and an Assistant Professor, Department of Physical Medicine and Rehabilitation, Weill Cornell Medical College. Topics for commentary/opinion from Dr. Stampas: Spinal Cord Injury Rehabilitation, Latest treatments for Spinal Cord Patients, Spinal Cord Paralysis, Multiple Sclerosis, Parkinsons Disease, Spasticity Management, Guillain-Barre syndrome, Will the paralyzed walk again? Argyrios Stampas, MD is the Director of Burke Rehabilitation Hospitals Spinal Cord Injury Program and an Assistant Professor, Department of Physical Medicine and Rehabilitation, Weill Cornell Medical College. Dr. Stampas has a wealth of knowledge and experience in Physical Medicine and Rehabilitation and specialized experience in the treatment of patients with spinal cord injuries. Dr. Stampas is a graduate of the State University of New York Upstate Medical University and completed his residency at the University of Pennsylvania in Physical Medicine and Rehabilitation. Prior to joining Burke, Dr. Stampas was affiliated with Johns Hopkins University and the prestigious International Center for Spinal Cord Injury at the Kennedy Krieger Institute. While there, he completed a fellowship in Spinal Cord Injury Medicine. … Continue reading →

The central nervous system includes the brain and spinal cord. The peripheral nervous system is comprised of all the nerve branches that leave the skull or spine to feed the individual muscles and areas of sensation. The most dramatic difference between the two systems is that, unlike the peripheral nerves, once the human brain or spinal cord is injured, they are essentially incapable of significant regeneration. Damage for the most part is permanent, and this limitation is consistent for all mammals, not just for humans. Scientists continue to study ways to change this natural boundary hoping to someday stimulate the spinal cord or brain to repair itself, but the inroads have been small. The peripheral nerves, however, have been given the miraculous capability to regenerate and repair themselves. The process of how a nerve dies back after injury, and then begins the process of repair, has been studied in detail since the first experiments by Augustus Waller in 1951. Waller was a British physician who made his discoveries through detailed studies on frogs, identifying the first steps that occur when a nerve is injured. The process remains well known today among scientists as Wallerian degeneration. Once a peripheral nerve injury … Continue reading →

Mar. 27, 2013 An international team of scientists, led by researchers at the University of California, San Diego School of Medicine, says a key protein in Schwann cells performs a critical, perhaps overarching, role in regulating the recovery of peripheral nerves after injury. The discovery has implications for improving the treatment of neuropathic pain, a complex and largely mysterious form of chronic pain that afflicts over 100 million Americans. The findings are published in the March 27, 2013 issue of the Journal of Neuroscience. Neuropathic pain occurs when peripheral nerve fibers (those outside of the brain and spinal cord) are damaged or dysfunctional, resulting in incorrect signals sent to the brain. Perceived pain sensations are frequently likened to ongoing burning, coldness or "pins and needles." The phenomenon also involves changes to nerve function at both the injury site and surrounding tissues. Not surprisingly, much of the effort to explain the causes and mechanisms of neuropathic pain has focused upon peripheral nerve cells themselves. The new study by principal investigator Wendy Campana, PhD, associate professor in UC San Diego's Department of Anesthesiology, with colleagues at UC San Diego and in Japan, Italy and New York, points to a surprisingly critical role … Continue reading →

DUBLIN, March 25, 2013 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/t8zp6f/neuromodulation) has announced the addition of the "Neuromodulation Market - [Spinal Cord Stimulation (SCS), Vagus Nerve Stimulation (VNS), Gastric Electrical Stimulation (GES), Deep Brain Stimulation (DBS), Sacral Nerve Stimulation (SNS), & Transcranial Magnetic Stimulation (TMS)] - Forecasts to 2017" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Neuromodulation devices have emerged as one of the fastest growing segments of the medical device market due to high demand for minimally invasive and non-invasive treatment. With advancements in technology, neuromodulation is expected to become a promising therapeutic area and high growth industry in the next decade, as it offers symptomatic relief mainly from chronic pain, incontinence, heart failure, headache, depression, epilepsy, etc. The neuromodulation devices market includes deep brain stimulation, spinal cord stimulation, vagus nerve stimulation, sacral nerve stimulation and others external stimulation devices such as transcranial magnetic stimulation, and transcutaneous electrical nerve stimulation (TENS). The neuromodulation technique acts directly upon nerves or the target area where the activity of nerves is altered due to biological responses produced by electrical stimulation or drug infusion. These devices include small electrodes that are attached to the brain, the spinal cord, or peripheral nerves. These precisely placed … Continue reading →

ROCKVILLE, Md., March 25, 2013 /PRNewswire/ --Neuralstem, Inc. (NYSE MKT: CUR) announced today that it secured $8 million in debt financing with Hercules Technology Growth Capital (HTGC), to fund the company's capital budget through late 2014. (Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO) "This debt financing extends our cash runway well into late 2014 at a critical time in our clinical product development cycle. We have multiple NSI-566 cell therapy clinical trials planned this year, building on our successful ALS Phase I trial, including the upcoming phase II ALS in the U.S.; both chronic and acute spinal cord injury in the U.S. and South Korea, respectively; ALS in Mexico, and stroke in China, in addition to completing the NSI-189/Phase Ib trial in major depressive disorder," said Neuralstem's President and CEO Richard Garr. "We are pleased to have the support of leading life sciences and technology investor, Hercules." "Neuralstem's unique stem cell platform has the potential to address a serious unmet medical need in the ALS and spinal cord injury patient populations, as well as other indications. The team's progress to date is the result of years of meticulous research and development. We are proud to be a strong financial partner," said Chad Norman, managing director … Continue reading →

Stem Cell Treatment for Spinal Cord Injury at the Stem Cell Institute in Panama - Daniel Campbell After stem cell therapy at the Stem Cell Institute in Panama, Daniel Campbell describes how his condition has improved since his first treatment. Daniel is i... By: cellmedicine … Continue reading →

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today reported financial results for the year ended December 31, 2012 and provided a business update. InVivo has pioneered a new treatment platform utilizing a variety of biocompatible polymer-based devices to provide structural support to a damaged spinal cord in order to spare tissue from scarring while improving functional recovery and prognosis after a traumatic SCI. Today there is no effective treatment for the spinal cord for paralysis caused by SCIs, and the market potential is estimated to be over $10 billion. "The year 2012 has quickly become our most productive. We grew our research and development teams to support a pipeline that now exceeds seven new treatment options for neurotrauma, and weve established a GMP manufacturing facility capable of manufacturing our scaffold and hydrogels for human use, said Frank Reynolds, InVivo Chief Executive Officer. Were ready to start a first-in-man clinical trial of our biopolymer scaffolding in acute SCI patients, and we expect as many as five products to be either on the market or in clinical studies by the end of 2014. … Continue reading →

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today announced that the Company has renewed its support for the Greater Boston Chapter of the National Spinal Cord Injury Association (NSCIA), a non-profit organization that offers programs and services to those with spinal cord injury and disease. InVivo will serve as a Premier sponsor at the RISE Above Paralysis Gala this Saturday, March 16, 2013, an annual event hosted by the Greater Boston Chapter of the NSCIA. The evening will bring together individuals with SCI, family members, healthcare professionals, and benefactors for a silent auction, dinner and dancing. This years gala marks the 21st anniversary of the Greater Boston Chapter. Weve worked for years to be ready to begin human studies and as we await word from the FDA regarding our application were proud to once again be a part of the RISE Above Paralysis Gala, said Frank Reynolds, InVivo Chief Executive Officer. This is the fourth year that weve been a premier sponsor, and we look forward to another evening celebrating the lives of those living with SCI. Said David Estrada, Director of … Continue reading →

Spinal Cord Injury Treatment and Symptoms XXXXXX◅ Spinal Cord Injury treatment mdash; Finding the right information about Spinal Cord Injury treatment symptoms, is crucial to managing Spinal Cord Injur... By: MainMDcom … Continue reading →

Mar. 7, 2013 Every year thousands of people in Europe are paralysed by a spinal cord injury. Many are young adults, facing the rest of their lives confined to a wheelchair. Although no medical cure currently exists, in the future they could be able to walk again thanks to a mind-controlled robotic exoskeleton being developed by EU-funded researchers. The system, based on innovative 'Brain-neural-computer interface' (BNCI) technology -- combined with a light-weight exoskeleton attached to users' legs and a virtual reality environment for training -- could also find applications in the rehabilitation of stroke victims and in assisting astronauts rebuild muscle mass after prolonged periods in space. In the United Kingdom, every eight hours someone suffers a spinal cord injury, often leading to partial or full lower-body paralysis. In the United States, more than 250 000 people are living with paralysis as a result of damage to their spinal cord, usually because of a traffic accident, fall or sporting injury. Many are under the age of 50, and with no known medical cure or way of repairing damaged spinal nerves they face the rest of their lives in a wheelchair. But by bypassing the spinal cord entirely and routing brain … Continue reading →